Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm, Inc. to Report Fourth Quarter and Year End 2015 Results

GlobeNewswire March 2, 2016

KemPharm to Present Data From Oral Human Abuse Liability Study for Investigational Drug KP201/APAP at the 2016 AAPM Annual Meeting

GlobeNewswire February 19, 2016

KemPharm, Inc. to Present at Upcoming Investor Conferences

GlobeNewswire February 18, 2016

FDA Grants Priority Review to KemPharm for KP201/APAP NDA

GlobeNewswire February 10, 2016

KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021

GlobeNewswire February 9, 2016

KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021

GlobeNewswire February 4, 2016

KemPharm Added to NASDAQ Biotechnology Index

GlobeNewswire January 7, 2016

KemPharm, Inc. Expands Pain Therapy Pipeline With Discovery of KP746

GlobeNewswire December 30, 2015

Factors Moving Markets - New Research on Franklin Covey, SeaChange International, KemPharm and Bravo Brio Restaurant

Accesswire December 17, 2015

KemPharm Submits NDA for KP201/APAP and Requests Priority Review From the FDA

GlobeNewswire December 15, 2015

KemPharm, Inc. to Present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY

GlobeNewswire December 3, 2015

KemPharm, Inc. Reports Q3 2015 Results

GlobeNewswire November 12, 2015

KemPharm, Inc. to Report Third Quarter 2015 Results

GlobeNewswire November 5, 2015

KemPharm, Inc. Completes Human Abuse Liability Program for KP201/APAP

GlobeNewswire October 21, 2015

KemPharm Enhances U.S. and Global Intellectual Property Estate

GlobeNewswire October 13, 2015

KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP

GlobeNewswire September 30, 2015

KemPharm Expands Its Abuse-Deterrent Opioid Pipeline With New Acetaminophen-Free, Immediate Release Hydrocodone and Immediate Release Oxycodone Prodrug Product Candidates

GlobeNewswire September 24, 2015

KemPharm to Highlight the Potential of Prodrugs at the 9th Annual Pain & Migraine Therapeutics Summit

GlobeNewswire September 23, 2015

KemPharm Data to be Presented at PAINWeek 2015

GlobeNewswire September 8, 2015

KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results

GlobeNewswire August 13, 2015